Heart Test Laboratories’ (HSCS) Buy Rating Reiterated at Maxim Group

Maxim Group reiterated their buy rating on shares of Heart Test Laboratories (NASDAQ:HSCS) in a research report released on Wednesday,Benzinga reports. Maxim Group currently has a $12.00 price objective on the stock.

Separately, Ascendiant Capital Markets reiterated a “buy” rating and issued a $15.00 price objective on shares of Heart Test Laboratories in a report on Monday, September 23rd.

Heart Test Laboratories Trading Up 12.0 %

NASDAQ:HSCS opened at $3.83 on Wednesday. The stock has a market cap of $3.50 million, a price-to-earnings ratio of -0.18 and a beta of 3.23. The company has a quick ratio of 4.02, a current ratio of 4.49 and a debt-to-equity ratio of 0.08. The company’s 50 day moving average price is $3.24 and its 200-day moving average price is $3.78. Heart Test Laboratories has a 52 week low of $2.36 and a 52 week high of $18.50.

Heart Test Laboratories (NASDAQ:HSCS) last released its quarterly earnings data on Monday, December 16th. The company reported ($2.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.30) by $0.03. During the same period in the prior year, the firm earned ($15.92) earnings per share. On average, equities research analysts forecast that Heart Test Laboratories will post -9.82 earnings per share for the current fiscal year.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.